Adiponectin and Metabolic Syndrome

By Yuji Matsuzawa, T. Funahashi, S. Kihara, I. Shimomura. Arteriosclerosis, Thrombosis and Vascular Biology, 2004

1,224 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/d9cde89eb2fed5cabe005b0f96ea4c9d874e4340

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Hannele Yki-Järvinen
2. Marja-Riitta Taskinen
3. Jaspinder Kaur

In Epidemiology

1. Hannele Yki-Järvinen
2. Mihai G. Netea
3. Jaspinder Kaur
4. A. Gressner

In Physiology

1. Hannele Yki-Järvinen
2. Marja-Riitta Taskinen
3. Jaspinder Kaur

Citations in the corpus

• A Comprehensive Review on Metabolic Syndrome (2014, background): “It has a multifactorial antiatherogenic action which includes an inhibition of endothelial activation, a reduced conversion of macrophages to foam cells, and inhibition of the smooth muscle proliferation and arterial remodelling that characterizes the development of the mature atherosclerotic plaque”
• Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial (2010, background): “Adiponectin is an adipocyte-derived serum protein that has important roles in the regulation of lipid and glucose metabolism (Matsuzawa et al., 2004), and is present in the blood as three multimers: LMW (trimer), MMW (hexamer) and HMW (12- to 18-mers) multimers (Waki et al.”
• Overproduction of large VLDL particles is driven by increased liver fat content in man (2006, background): “By activating peroxisome proliferator activated receptor (PPAR)α, adiponectin may be pivotal in upregulating the expression of key enzymes of fatty acid oxidation [14].”
• Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. (2004, background): “Therapy with adiponectin may be advantageous in reversing insulin resistance in lipodystrophic disorders and metabolic syndrome (114).”
• The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. (2007, background): “In particular, adiponectin plays an important role in the mechanisms that maintain the sensitivity to insulin, and its plasma concentration is inversely related to the degree of insulin resistance (104).”